Dysautonomia is not classified as an autoimmune disease. It is an umbrella term for any disorder of the autonomic nervous system, the network that controls heart rate, blood pressure, digestion, temperature, and other functions you don’t consciously manage. However, autoimmunity is increasingly recognized as one of the major drivers behind several forms of dysautonomia, and a significant percentage of patients carry detectable autoantibodies. The relationship between the two is real, complex, and still being defined.
Why Dysautonomia Isn’t a Single Disease
Dysautonomia doesn’t signify a specific diagnosis. It’s a category that covers a wide variety of autonomic symptoms, disturbances, and disorders. Some authorities have resisted adopting it as a formal term precisely because it doesn’t point to one condition. Instead, it includes specific diagnoses like postural orthostatic tachycardia syndrome (POTS), neurally mediated syncope, orthostatic hypotension, and inappropriate sinus tachycardia, along with cases of undifferentiated autonomic dysfunction that don’t neatly fit any of those labels.
These conditions can be primary, meaning the autonomic nervous system itself is the main problem, or secondary to another disease entirely. Diabetes, Parkinson’s disease, alcoholism, and autoimmune conditions like Sjögren’s syndrome can all damage or disrupt autonomic function. So asking whether dysautonomia is autoimmune is a bit like asking whether a fever is caused by infection: sometimes yes, sometimes no, and the answer depends entirely on what’s driving it in each person.
The Autoimmune Evidence in POTS
POTS is the most common form of dysautonomia, and it’s where the autoimmune evidence is strongest. For years, the condition was classified into subtypes based on what seemed to go wrong: nerve damage (neuropathic), low blood volume (hypovolemic), or excessive adrenaline activity (hyperadrenergic). In the past decade, researchers have focused heavily on autoimmunity as a mechanism that may cut across all of those categories.
A study published in the Journal of the American Heart Association tested 55 POTS patients for antibodies that target receptors on nerve cells. The results were striking. Eighty-nine percent of patients had elevated antibodies against the alpha-1 adrenergic receptor, which helps regulate blood vessel constriction. Fifty-three percent had elevated antibodies against a receptor involved in the body’s “rest and digest” signaling (the muscarinic M4 receptor). Only 9% of POTS patients had no detectable antibody elevations at all, compared to healthy controls who showed none.
These antibodies don’t just float harmlessly in the blood. They bind to receptors that directly control cardiovascular and autonomic function, which could explain symptoms like rapid heart rate on standing, blood pressure instability, and digestive problems. Still, the presence of antibodies alone doesn’t prove they’re causing the symptoms in every patient, and not every POTS case shows the same antibody profile.
Autoimmune Autonomic Ganglionopathy
One form of dysautonomia is definitively autoimmune. Autoimmune autonomic ganglionopathy (AAG) is caused by antibodies that attack the ganglionic acetylcholine receptor, a critical relay point in the autonomic nervous system. This is the most well-established autoantibody marker in autoimmune dysautonomia, and it can cause widespread autonomic failure affecting blood pressure, heart rate, sweating, bladder function, and the gut. AAG is rare compared to POTS but serves as proof of concept that the immune system can directly disable autonomic pathways.
Autoimmune Diseases That Cause Dysautonomia
Even when dysautonomia itself isn’t autoimmune in origin, it frequently shows up alongside autoimmune conditions. Sjögren’s syndrome is one of the clearest examples. In a study of 317 patients with primary Sjögren’s, nearly 55% had scores indicating autonomic dysfunction, compared to 20% of community controls. These autonomic symptoms weren’t minor side effects. They contributed meaningfully to overall symptom burden and correlated with disease activity.
Lupus, rheumatoid arthritis, celiac disease, and multiple sclerosis can also trigger secondary dysautonomia through inflammation, nerve damage, or immune-mediated injury to the autonomic system. In these cases, treating the underlying autoimmune disease sometimes improves autonomic symptoms as well.
Post-Viral Dysautonomia and the Immune System
The surge of long COVID cases brought new attention to how viral infections trigger autonomic dysfunction. Researchers have identified several potential mechanisms: damage to the lining of blood vessels, reactivation of dormant viruses, overactivation of immune cells called mast cells, and a chronic stress response that keeps the body locked in a fight-or-flight state. What remains unclear is whether these problems stem from the virus directly injuring the brainstem and blood vessels, or from the immune system staying persistently activated long after the infection clears.
This distinction matters because if the immune system is the ongoing problem, immune-targeted treatments might help. If the damage is structural, the treatment approach is different. Many post-viral dysautonomia patients likely have some combination of both.
How Autoimmune Dysautonomia Is Tested
If your doctor suspects an autoimmune cause, there are specific blood tests that screen for relevant antibodies. Mayo Clinic Labs offers an autoimmune dysautonomia panel that checks for ganglionic neuronal antibodies (the AAG marker), along with several other antibodies associated with immune-mediated or cancer-related autonomic dysfunction.
The standard panels don’t catch everything, though. In one study of 38 patients with refractory autoimmune dysautonomia, only 13% tested positive on the traditional Mayo autoimmune dysautonomia panel. But when researchers tested for less commonly screened antibodies, specifically antiphospholipid antibodies and a newer set of Sjögren’s-related antibodies, 76% and 42% tested positive, respectively. This suggests that many patients with immune-driven dysautonomia are being missed by standard testing.
Immune-Targeted Treatment
The standard approach to dysautonomia focuses on managing symptoms: increasing fluid and salt intake, wearing compression garments, exercise programs, and medications that address heart rate or blood pressure. These remain the accepted standard of care. But for patients who don’t respond, treatments that target the immune system are showing promise.
In a retrospective study of 38 patients with severe, treatment-resistant autoimmune dysautonomia who received immune-modulating therapy for at least three months, 83.5% improved. Before treatment, the average patient was mostly bedridden, functioning at about 21% of normal capacity. After at least a year of treatment, responsive patients reached 74%, nearing the ability to return to work or school. The first signs of improvement appeared at an average of 5.3 weeks, and no serious side effects were reported.
These results are encouraging but come from a small, retrospective study without a placebo comparison. Researchers have called for randomized controlled trials to confirm these findings. For now, immune-targeted treatment is generally considered only for severely affected patients who haven’t responded to conventional approaches, and it works best when there’s blood test evidence supporting an autoimmune mechanism.
Where the Classification Stands
Dysautonomia as a whole is not an autoimmune disease. It is a broad category with many possible causes, autoimmunity being one of them. But the autoimmune subset appears to be larger than previously recognized. When nearly 90% of POTS patients in one study carry antibodies targeting autonomic receptors, and more than half of Sjögren’s patients show autonomic dysfunction, the overlap between autoimmunity and dysautonomia is substantial. The field is moving toward recognizing autoimmune mechanisms as central rather than peripheral to many dysautonomia cases, even if the formal classification hasn’t caught up yet.